Novo Nordisk Stock Plummets Following Weight Loss Drug Trial Fail

Novo Nordisk shares plummeted after its weight loss drug CagriSema failed to demonstrate non-inferiority against Eli Lilly's tirzepatide in a head-to-head trial.Eli Lilly's drug Zepbound achieved 25.5% weight loss compared to 23% for CagriSema over 84 weeks, solidifying its market leadership.James Shin of Deutsche Bank and Jim Cramer highlighted the widening gap as Novo Nordisk faces rising competition and falling prices in the USA.